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Hepatitis B virus (HBV) infections represent a global health problem, since these account for 350
million chronic infections worldwide that result in 500000–700000 deaths each year. Control of
viral replication and HBV-related disease and mortality are of utmost importance. Because the
currently available antiviral therapies all have major limitations, new strategies to treat chronic HBV
infection are eagerly awaited. Six single-domain antibodies (VHHs) targeting the core antigen of
HBV (HBcAg) have been generated and three of these bound strongly to HBcAg of both subtype
ayw and adw. These three VHHs were studied as intrabodies directed towards the nucleus or the
cytoplasm of a hepatoma cell line that was co-transfected with HBV. A speckled staining of
HBcAg was observed in the cytoplasm of cells transfected with nucleotropic VHH intrabodies.
Moreover, an increased intracellular accumulation of hepatitis B e antigen (HBeAg) and a
complete disappearance of intracellular HBcAg signal were observed with nuclear targeted
HBcAg-specific VHHs. These results suggest that HBcAg-specific VHHs targeted to the nucleus
affect HBcAg and HBeAg expression and trafficking in HBV-transfected hepatocytes.
INTRODUCTION
Control of the replication cycle of hepatitis B virus (HBV)
is of vital importance since there are still 2 billion people
worldwide infected with HBV and 350 million suffering
from a chronic infection. Approximately 15–40% of these
chronically infected people will develop cirrhosis, liver
failure and hepatocellular carcinoma (HCC), leading to
500 000–700 000 deaths each year (Lavanchy, 2004).
Therapies with interferons (IFNs) and nucleos(t)ide
analogues are the only approved treatments for chronic
HBV infections, but these all have serious drawbacks
(Hilleman, 2003; Seeger et al., 2007).
Novel approaches are currently being explored to tackle
HBV infection. The hepatitis B core antigen (HBcAg) is an
attractive target for new therapeutic candidates. This
molecule is the structural unit of the nucleocapsid, which
surrounds the partially double-stranded viral DNA genome
within the viral particle. Nucleocapsids are formed of 180
or 240 HBcAg monomers in the cytoplasm, encapsidating
one copy of viral pre-genomic RNA (pgRNA) (Bruss, 2004,
2007). After conversion of the pgRNA into a mature viral
genome, the nucleocapsid moves to the endoplasmic
reticulum (ER) where it interacts with the ER mem-
brane-embedded viral envelope proteins. This results in the
construction of a complete viral particle, which is
transported further in the secretory pathway. Finally, the
particles are secreted into the bloodstream. The cytoplas-
mic mature nucleocapsids can also move back to the
nucleus, disintegrate into individual HBcAg molecules in
the nuclear pore complex and finally release the viral
genome into the nucleus (Kann et al., 2007; Rabe et al.,
2003). The number of nuclear viral genomes is amplified
by this recycling mechanism (Tuttleman et al., 1986).
HBcAg proteins in the nucleus function as transcriptional
inhibitors of the IFN-induced antiviral MxA protein
(Gordien et al., 2001; Rosmorduc et al., 1999). These
individual HBcAg molecules in the nucleus can again
reassemble into nucleocapsids. The biological role of this
nuclear capsid remains unresolved. It has been shown, by
several research groups, that the presence of capsid in the
nucleus is correlated with a high level of viral replication
and a low degree of hepatocyte proliferation (Kim et al.,
2006; Serinoz et al., 2003).
Several core-specific small molecule antivirals have shown
that HBcAg is indeed a good candidate for inhibition of
HBV replication (Feld et al., 2003; Xu et al., 2003). These
core-specific antivirals may act at either the RNA level or
the protein level. Efficient viral inhibition by targeting the
core RNA, which is in fact the pgRNA, has already been
demonstrated with RNA interference (Ying et al., 2003),
antisense oligonucleotides (Ji & Si, 1997) and ribozymes
(Feng et al., 2001). HBcAg has also been targeted at the
protein level by aptamers (Butz et al., 2001),
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HeteroArylDihydropyrimidines or HAPs (Deres et al.,
2003) and single-chain variable fragment (scFv) intra-
bodies (Yamamoto et al., 1999).
Recently, we have described the inhibitory potential of
VHH intrabodies directed against the most abundant
domain, S, of the envelope proteins of HBV. A more than
two log reduction in virion secretion was observed in mice
11 days after the injection of a plasmid coding for an anti-S
VHH intrabody (Serruys et al., 2009). Based on the
successful targeting by experimental small molecule drugs
against HBcAg, we have explored whether VHH intra-
bodies against HBcAg are able to inhibit HBV replication.
In this report, we describe the production and biochemical
characterization of HBcAg-specific VHH molecules. We
studied the expression of the corresponding VHH
intrabodies in the cytoplasm as well as in the nucleus and
tested these in a cellular HBV model.
RESULTS
Isolation and selection of HBcAg-specific VHHs
Two llamas were immunized with recombinant HBcAg
(Diasorin, subtype ayw) to induce the production of
HBcAg-specific antibodies. The VHH phage library was
created as described previously (Serruys et al., 2009). The
VHH entities of the library were expressed on phages after
infection of the bacteria with the helper phage M13K07.
Selection of HBcAg-specific VHHs was performed by one
round of biopanning. Ninety-four bacterial colonies were
randomly chosen and induced for the secretion of soluble
VHH molecules that were screened for target specificity by
a VHH-screening ELISA. Eighty per cent of all VHH–p3
fusion proteins bound their antigen. The presence of VHH-
coding phagemids in the bacteria was confirmed by colony
PCR. HinfI fingerprinting showed 34 VHH-coding genes
with a different restriction pattern. These were sequenced,
aligned and subdivided into 21 families. Finally, six
HBcAg-specific VHHs were selected (C1–C6) based on
their sequence (Fig. 1) and on their antigen-binding
capacity (Table 1). As a negative control, VHH NC, a
VHH molecule that does not bind HBcAg, was used
(Serruys et al., 2009).
Characterization of HBcAg-specific VHH
molecules
Binding of the VHH molecules to HBcAg was studied by a
VHH-binding ELISA using HBcAg, taken from two HBV
strains, one with HBcAg subtype ayw and the other with
HBcAg subtype adw. The non-HBcAg-specific VHH NC
and a monoclonal mouse anti-HBcAg antibody were
included as negative and positive controls, respectively.
Based on the obtained optical density, the VHHs were
divided into two groups (Fig. 2a). The first group consisted
Fig. 1. Amino acid sequences of the six selected HBcAg-specific VHHs (C1–C6) and the non-HBcAg-specific VHH (NC).
The framework regions (FR) and complementary determining regions (CDR) are indicated. CDR1 is highlighted in red, CDR2 in
green and CDR3 in blue. Residues in purple represent residues that are characteristic for camelids. Residues in orange
represent cysteines that can form disulphide bridges.
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of VHHs C2, C4 and C6 which bound very well to both
ayw and adw HBcAg and also elicited the best signal in the
VHH-screening ELISA (Table 1). VHHs C2 and C4 bound
to HBcAg at the same level as the positive control mouse
anti-HBc. Taking into account that these VHHs are
monovalent while the monoclonal antibody (mAb) is a
bivalent molecule, these results indicated that the VHHs
probably have a high affinity for their antigen. The second
group consisted of VHHs C1, C3 and C5 which induced a
lower signal in the VHH-binding ELISA, with a very weak
binding of C3 and no binding of C5 to subtype adw.
The sequences of both HBcAg preparations are described
in Supplementary Fig. S1 (available in JGV Online). The
major sequence differences are situated within or sur-
rounding the immunodominant tip of HBcAg. The
difference in binding signal of VHHs C3 and C5 to the
two HBcAg molecules suggests that this tip may be part of
the epitope. The importance of this region for C3 and C5
has also been demonstrated by the loss in binding to an
ayw HBcAg mutant with a deletion within the tip
(Supplementary Fig. S2). The binding of C2, C4 and C6
to this deletion mutant was also abolished, suggesting that
the tip is also important for these VHHs although
differences in the amino acid composition in the tip with
adw HBcAg did not seem to affect the binding. In contrast,
VHH C1 bound equally well to the wild-type HBcAg ayw
as to its deletion mutant, suggesting that the epitope of C1
is not located in the tip. Indeed, although C1 has no high
binding capacity for HBcAg, it bound to both HBcAg ayw
and adw.
The anti-HBcAg activity of the VHHs was studied further
by a routine qualitative competition assay for anti-HBcAg
detection (AxSYM CORE, Abbott). According to the
manufacturer’s guidelines, serum samples with a signal-
to-cutoff (S/Co) ratio of less than 1.0 were considered
positive for anti-HBcAg antibodies. VHHs C2 and C4 gave
a positive result with±70 nM (approximately 1 mg ml21)
(Fig. 2b), suggesting that they did interfere with the
binding of the detection antibodies of the commercial test
kit. The other VHHs were negative in the competition
assay.
HBcAg and hepatitis B e antigen (HBeAg) are both
translated from the pgRNA, initiating from different start
codons within the same open reading frame. Therefore,
HBcAg and HBeAg share a large part of their amino acid
sequence. In contrast with HBcAg, HBeAg is produced in a
non-particulate form and is secreted into the bloodstream
as dimers. Despite their differences in conformation and
coding sequence, HBcAg and HBeAg share antigenic
epitopes. Therefore, we checked if the VHHs were cross-
reactive for HBeAg. VHHs C4 and C6 indeed bound
HBeAg (Fig. 2c), while the other VHHs did not show any
cross-reactivity.
Based on the results of the VHH-binding ELISA, only the
strong binders C2, C4 and C6 were investigated in more
detail.
Cloning the VHH coding sequence in a eukaryotic
vector
HBcAg exerts its functions in different compartments of
the infected cell. Cytoplasmic localization is required for
the formation of the nucleocapsid first and of complete
viral particles thereafter (Bruss, 2004, 2007), while nuclear
localization of HBcAg is required to fulfil the role of IFN
inhibitor (Gordien et al., 2001; Rosmorduc et al., 1999)
and is thought to be associated with high-level replication
(Kim et al., 2006; Serinoz et al., 2003). To interfere with
these different functions of HBcAg, expression of HBcAg-
specific VHHs as intrabodies was targeted to the cytoplasm
as well as to the nucleus. For this, the VHH coding
sequence and the adjoining His-tag were cloned into the
cytoplasmic plasmid pCMV/myc/cyto and in the nuclear
plasmid pCMV/myc/nuc (pShooter; both Invitrogen),
using the NcoI and NotI restriction sites. The nuclear
vector contains a triple nuclear localization signal from the
SV40 large T antigen. Because the coding sequence of
VHHs C2, C4 and C6 contains an internal NcoI restriction
site, a nucleotide substitution without any change in the
amino acid composition was performed prior to the
construction of the corresponding pShooter vectors.
Effect of the VHHs in a cellular HBV model
We previously used the HBV coding plasmid pSP65ayw1.3
(a kind gift from Frank Chisari, The Scripps Research
Insitute) which encodes HBcAg subtype ayw (GenBank
accession no. V01460) (Serruys et al., 2009). To examine
the effect of the VHHs on HBcAg of subtype adw as well as
ayw, another pSP65 plasmid coding for HBcAg of subtype
adw (GenBank accession no. 51970) (produced by
GeneArt, Regensburg) was constructed. This new vector
was called pSP65adw1.3. To compare the production of
viral proteins of both plasmids, a series of electroporations
were performed and the levels of secreted hepatitis B
surface antigen (HBsAg) and HBeAg, and the amounts of
intracellular HBcAg were determined. All data were
comparable for both HBV plasmids (Fig. 3a), implying
that the introduction of adw HBcAg to the plasmid did not
negatively affect the production of viral proteins. Both
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plasmids are consequently equivalent for the study of VHH
activity.
Before the antiviral capacity of the VHHs was investigated,
a sandwich-VHH-binding ELISA was performed to
investigate if the VHHs recognized expressed HBcAg of
cells transfected with 10 mg HBV plasmid. Therefore, 45 mg
total lysate was added to a rabbit anti-core coated
Maxisorp plate. Binding of Escherichia coli-purified VHH
with HBcAg lysate was compared to binding with
commercially available recombinant HBcAg preparations.
All three VHH molecules recognized ayw HBcAg as well as
adw HBcAg in the lysates (Fig. 3b), thus confirming that
VHHs recognize nucleocapsids produced by HBV plasmid-
transfected hepatoma cells in addition to recombinant
nucleocapsid.
The optimal harvesting time point and concentration of
transfected HBV plasmid needed to obtain the highest
yield of HBcAg was determined before the effect of co-
expression of VHH intrabodies was investigated. For
this, the hepatoma cell line HepG2 was transfected with
Fig. 2. Binding characteristics of the HBcAg-specific VHHs (C1–C6), the non-HBcAg-specific VHH NC as negative control
and a monoclonal mouse anti-HBcAg antibody as a positive control. (a) Study of the binding of the E. coli-purified VHH
molecules on HBcAg subtypes ayw and adw by a VHH-binding ELISA. (b) Detection of anti-HBcAg activity by AxSYM CORE.
(c) Binding of the VHH molecules on 1 mg ml”1 coated HBeAg. A monoclonal (mAb) and a polyclonal (pAb) anti-core antibody
were included as control antibodies.
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various amounts of HBV plasmid (5, 10, 25 and 50 mg),
complemented with stuffer empty pShooter plasmid, to
obtain a total of 50 mg DNA. The cells were lysed at 1, 2
or 3 days post-electroporation. Transfection of 25 and
50 mg HBV plasmid did not result in a sufficient number
of viable cells, suggesting that a high amount of HBV
plasmid was toxic for the cells. Consequently, the HBcAg
level was not determined for the transfections using 25
and 50 mg HBV plasmid. Transfections with 5 and 10 mg
were not toxic and the highest quantity of HBcAg was
measured at 3 days after transfection with 10 mg HBV
DNA (Table 2). Therefore, further transfections to study
the effect of VHH intrabodies on HBV were performed
with 10 mg HBV plasmid. This was further complemen-
ted with 2 mg pShooter VHH plasmid and 8 mg empty
pShooter vector, resulting in a total of 20 mg plasmid.
Three days post-electroporation, supernatant was col-
lected and lysates were prepared or cells were immuno-
stained for confocal microscopy.
Confocal microscopy analysis showed that the VHHs were
present in the targeted compartments: cytoplasm-directed
VHH was localized in the cytoplasm and nucleus-targeted
VHH was predominantly present in the nucleus (Fig. 4 and
Supplementary Fig. S3). This indicates that the VHH
molecules were efficiently expressed in the reducing
environment of the cytoplasm and transported to the
nucleus, despite the lack of disulphide bridges. The cells
were also stained for HBcAg to examine whether the
HBcAg-specific VHHs had any influence on the cellular
distribution of HBcAg. No difference was observed in
HBcAg distribution between the cytoplasm-directed VHHs
and the negative control groups. All groups showed a
diffuse cytoplasmic staining. In contrast, a more speckled
distribution of HBcAg was noted in the cytoplasm with the
HBcAg-specific VHHs directed to the nucleus, suggesting
that nuclear VHHs affect HBcAg distribution.
Next, the levels of secreted and intracellular HBsAg and
HBeAg were determined to see if the VHHs influenced the
Fig. 3. (a) Comparison of cells transfected with 10 mg ayw or adw HBV plasmid for the secretion of HBsAg (i) and HBeAg (ii)
and the amount of intracellular HBcAg (iii). (b) A sandwich-VHH-binding ELISA was performed to study VHH binding to HBcAg
present in 45 mg total lysate obtained following transfection of cells with 10 mg HBV plasmid. The binding of VHH to this
material was compared with that of commercially available HBcAg (50 ng ml”1; Control). Filled bars, ayw; open bars, adw.
Table 2. Determination of the optimal harvesting point and
concentration of HBV plasmid needed to obtain the highest
amount of HBcAg, by using an HBcAg-binding assay
Values represent the OD450. NA, Not applicable.
Days post-transfection
HBV plasmid Amount (mg) 1 2 3
Negative control NA 0.101 0.098 0.097
Ay 5 0.107 0.160 0.206
10 0.118 0.192 0.242
Ad 5 0.106 0.162 0.194
10 0.154 0.341 0.312
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production and secretion of other viral proteins (Fig. 5).
The amount of secreted HBsAg and HBeAg was compar-
able for all groups (Fig. 5a), as was the amount of
intracellular HBsAg. In contrast, an increase in intracellular
HBeAg was demonstrated when the VHHs C2 and C6 were
localized in the nucleus (Fig. 5b). This elevation was
predominantly observed with the adw HBV plasmid and
was also demonstrated with 10 mg instead of 2 mg VHH
plasmid (Supplementary Fig. S4). No difference in the
amount of secreted viral particles was observed.
Finally, the amount of capsid in the lysates was determined
using an HBcAg detection ELISA. The HBcAg signal
dropped to background levels with all nuclear HBcAg-
specific VHHs, while the non-HBcAg-specific VHH NC
had no effect on the amount of HBcAg detected (Fig. 6). In
summary, the elevated intracellular amount of HBeAg and
the observed absence of HBcAg in lysates with VHHs
targeted to the nucleus suggest that these specifically affect
HBcAg and HBeAg pathways.
DISCUSSION
In this study, we describe the production and in vitro
characterization of six VHH molecules directed against
HBcAg. The binding affinity for HBcAg of three of these
VHHs (C2, C4 and C6) was comparable with that of a
Fig. 4. Immunofluorescent staining of HBcAg
(green), VHH (red) and nuclei (blue). HepG2
cells were transfected with 10 mg pSPayw1.3
or pSPadw1.3 plasmid, 2 mg VHH–pShooter
vector pCMV/myc/cyto (a) or pCMV/myc/nuc
(b) and 8 mg empty pShooter plasmid (3 days
post-electroporation). A negative control elec-
troporation was performed without VHH–
pShooter plasmid (c). Cotransfection with a
nuclear-directed VHH shows a speckled
HBcAg pattern. The complete staining experi-
ment, including VHH and nuclei staining, is
shown in Supplementary Fig. S3.
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reference mAb (Fig. 2a). Taking into account that the VHHs
are monovalent while the mAb is bivalent, these VHH
molecules must have excellent antigen-binding properties.
VHHs C4 and C6 also bind to HBeAg, suggesting that these
bind an epitope shared by HBcAg and HBeAg. Furthermore,
C2 and C4 gave a positive result in the AxSYM CORE test
(Fig. 2b), indicating that these VHHs interfered with the
binding of the antibodies present in the kit. The negative
results of the other VHHs in the AxSYM CORE test may be
due to: (i) the smaller size of the VHHs compared with the
detection antibodies that bind the same epitope; (ii) the
binding of these VHHs on a different epitope to the
detection antibodies; or (iii) a lower affinity of the VHHs.
The latter was already suggested by the lower OD signal in
the VHH-screening ELISA and the VHH-binding ELISA,
especially for C1, C3 and C5.
The three E. coli-derived VHH molecules that strongly inter-
acted with recombinant HBcAg (C2, C4 and C6) were also
capable of binding capsids derived from ayw as well as adw
HBV-transfected HepG2 cells (Fig. 3b). This allowed the
study of these VHHs as cytoplasmic and nuclear intrabodies
in HBV-transfected cells and their possible effect on expres-
sion and assembly of HBcAg and/or other viral proteins.
The study of HBV-transfected cells showed an increase in
intracellular HBeAg with nuclear VHH intrabodies C2 and
C6, predominantly with adwHBV. This phenomenonmay be
caused by the interference of VHH intrabodies with the
formation of complete capsid particles. These non-particulate
HBcAg molecules may display HBeAg antigenicity, resulting
in their detection as HBeAg in the automated test. Another
hypothesis for the increase in intracellular HBeAg may be the
recognition of HBeAg by C2 and C6, resulting in retention
inside the cell. However, only C4 and C6 display cross-
reactivity for HBeAg (Fig. 2c). Moreover, the unchanged
secreted level of HBeAg does not support this view.
Confocal microscopy revealed a speckled staining of HBcAg
in the cytoplasm with nuclear HBcAg-specific VHHs (Fig. 4).
Fig. 5. Determination of HBsAg and HBeAg
levels in cell culture medium (a) and cell lysate
(b). HepG2 cells were transfected with 10 mg
pSPayw1.3 or pSPadw1.3 plasmid, 2 mg VHH–
pShooter vector and 8 mg empty pShooter
plasmid (3 days post-electroporation). S/N,
Signal-to-noise; S/Co, signal-to-cutoff.
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It is possible that the VHHs targeted to the nucleus indirectly
affect HBcAg in the cytoplasm, resulting in an accumulation
of HBcAg. Another possible explanation is that this signal
may be due to an accumulation of HBeAg instead of HBcAg.
Indeed, the polyclonal antibody used to detect HBcAg also
interacts with HBeAg (Fig. 2c). However, this result is not
consistent with the increased level of intracellular HBeAg by
AxSYM detection (Fig. 5b), since nuclear C4 also shows these
cytoplasmic speckles while the intracellular level of HBeAg
was not increased with nuclear C4.
In contrast with the results obtained using confocal
microscopy, only background levels of HBcAg in lysates
were observed with all nuclear VHHs (Fig. 6). No clear
explanation is available for the absence of this HBcAg
signal in the ELISA. Inhibition of HBcAg binding on the
coated anti-HBcAg antibody by VHH is unlikely because
the HBcAg level with co-expressed cytoplasmic VHH did
not give a background signal. Moreover, we have checked
whether an inhibition may occur by co-incubating HBcAg
with HBcAg-specific VHHs on an anti-HBcAg coated
plate. A limited inhibition of the signal was observed when
a very high concentration of VHH was applied (data not
shown). It is very unlikely that this interference is
responsible for the low levels of HBcAg in the lysates,
since these contained only small amounts of VHHs.
To our knowledge, this is the first report of a VHH
intrabody against HBcAg. Despite their preliminary
character, our data seem to indicate that HBcAg-specific
VHH intrabodies have an effect on the viral life cycle in
HBV-transfected hepatocytes. The molecular mechanism
of this VHH-mediated effect on HBV needs to be
elucidated in future experiments. The inability to detect
HBcAg in lysates of HBV-transfected cells that were
cotransfected with a nuclear VHH intrabody needs to be
examined in more detail. It may be worthwhile to examine
the effects of a combined transfection with a nuclear and a
cytoplasmic VHH construct to see if this results in a
stronger inhibition of HBV replication and particle
production. Study of these VHH intrabodies in vivo will
be of crucial importance to determine the antiviral
capacity. As previously demonstrated with the S-specific
VHHs, the antiviral effect observed in the in vivo model
was much more convincing than that obtained in the in
vitro cellular model. A combined targeting of HBsAg as
well as HBcAg with their respective VHH intrabodies may
also result in a more pronounced antiviral effect.
METHODS
Construction of the VHH phage display library and selection of
HBcAg-specific VHHs. This protocol was carried out as described in
the paper by Serruys et al. (2009).
VHH-binding ELISA. First, monomeric VHH molecules were
produced and purified, according to the protocol described by
Serruys et al. (2009). Maxisorp plates (Nunc) were coated with 1 mg
HBcAg ml21 (derived from HBV subtype ayw from Biodesign or HBV
subtype adw from GlaxoSmithKline) or 1 mg HBeAg ml21 (Diasorin).
The plates were blocked with PBS/1% BSA. After three washes with
PBS/0.1% Tween 20, VHHs were added at concentrations indicated on
the figures. Afterwards, mouse anti-myc was added (Roche), followed by
goat anti-mouse–horseradish peroxidase (HRP) conjugate (Sigma).
Fig. 6. Detection of intracellular HBcAg content in cells cotransfected with 10 mg pSPayw1.3 (a) or pSPadw1.3 (b) plasmid, 2 mg
VHH–pShooter vector and 8 mg empty pShooter plasmid (3 days post-electroporation). The presence of HBcAg in HBcAg-
specific VHH-transfected cells was compared with transfections without VHH (”) or with the non-HBcAg-specific VHH NC.
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Also, a twofold serial dilution of the mAb mouse anti-core (Biodesign)
was added to the coated plate as a positive control, followed by
incubation with anti-mouse–HRP conjugate. HRP activity was
determined with tetramethylbenzidine (TMB) substrate (Sigma). After
addition of 0.5 M H2SO4, the OD was read at 450 nm.
Cloning of the VHH coding sequence in the eukaryotic
pShooter vectors pCMV/myc/cyto and pCMV/myc/nuc. VHH
sequences were amplified using one of the forward primers (FW) and
the reverse primer RV. Since C2, C4 and C6 had an internal NcoI site,
this extra restriction site had to be removed prior to further
construction. For this, an extra amplification step was performed to
amplify the sequences upstream and downstream of this extra NcoI
site separately using the corresponding FW+RVintern primer and the
corresponding FWintern+RV primer, respectively. Both amplification
products were used for a final PCR with the FW and RV primers,
resulting in an amplified VHH sequence without the internal
restriction site. PCR primers are listed in Supplementary Table S1.
Next, PCR fragments were digested with NotI and NcoI and ligated
into the nuclear plasmid pCMV/myc/nuc or the cytoplasmic plasmid
pCMV/myc/cyto (pShooter, Invitrogen). Finally, E. coli TOP10 cells
(Invitrogen) were transformed with this ligation product.
Cells and transfections. HepG2 cells were grown in cRPMI medium
(RPMI medium, 10% fetal calf serum, 100 U penicillin ml21, 100 mg
streptomycin ml21, 1 mM sodium pyruvate, 2 mM L-glutamine) at
37 uC in a humidified 5% CO2 atmosphere. Twenty-four hours before
transfection, cells were transferred to cRPMI medium with 0.1 mM
dithiothreitol (DTT) and 10 mM glucose. Transfection of 46106 cells
with 20 mg plasmid was performed by electroporation at 250 V and 975
mF in 300 ml cRPMI (without fetal calf serum) with 0.1 mM DTT and
10 mM glucose. For lysate purposes, electroporated cells were
resuspended in 6 ml cRPMI and kept in a cell culture flask for 3 days.
For immunostaining purposes, the electroporated cells were resus-
pended in 9 ml cRPMI and 3 ml of this suspension was added to
coverslips in a six-well plate. Five–six hours after transfection, the
supernatant was replaced completely by fresh medium. Supernatant
(1 ml) was collected 3 days post-electroporation. HepG2 cells were
harvested by EDTA/trypsin treatment. After two washes with PBS, the
cells were lysed by five freeze/thaw cycles in 200 ml PBS/16 complete
protease inhibitor cocktail (Boehringer Mannheim). After centrifu-
gation, the protein concentration of the cleared cell lysate was measured
(protein assay dye reagent from Bio-Rad).
Sandwich-VHH-binding ELISA Maxisorp plates were coated with
10 mg rabbit-anti-HBcAg ml21 (Dako) for 2 h. The plates were
blocked with PBS/1% BSA. Forty-five micrograms total lysate or
50 ng purified HBcAg ml21 was added and incubated overnight at
4 uC. After five washes with PBS/0.05% Tween 20, 1 mg VHH ml21
was added and incubated for 1 h at room temperature. VHH
detection was performed by incubation with mouse anti-myc– and
goat anti-mouse–HRP. Also, mouse anti-HBcAg was added as a
positive control for HBcAg detection, followed by goat anti-mouse–
HRP incubation. HRP activity was determined with TMB substrate
and stopped by adding 0.5 M H2SO4. The OD was read at 450 nm.
HBcAg detection ELISA A Maxisorp plate was coated with 10 mg
rabbit anti-HBcAg ml21 (Dako) and coated with PBS/1% BSA.
Lysates were added at the concentrations indicated. After three washes
with PBS/0.05% Tween 20, detection of bound HBcAg was carried
out with mouse anti-HBcAg– and goat anti-mouse–HRP.
Analysis of HBV parameters in transfected cells. HBsAg and
HBeAg levels were determined in cell culture supernatant and lysates
with the HBsAg (V2) AxSYM test and HBeAg 2.0 AxSYM test
(Abbott), respectively. The detection limit for HBsAg is 2 signal-to-
noise (S/N) while for HBeAg the cutoff value is 1 signal-to-cutoff (S/
Co).
Immunostaining of electroporated HepG2 cells. Cells grown on
coverslips were washed with PBS, fixed with 4% paraformaldehyde,
permeabilized with 0.1% Triton X-100 and blocked in PBS/10% goat
serum for 30 min. VHHs were detected using mouse anti-myc and
goat anti-mouse AlexaFluor 546 (Molecular Probes). HBcAg was
detected with rabbit anti-HBcAg and goat anti-Rabbit 488 (Molecular
Probes). Nuclei were stained with DAPI (Molecular Probes).
Coverslips were mounted in Vectashield mounting medium
(Vector) and examined with a confocal laser scanning microscope
(Carl Zeiss Microscopes).
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